The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Targeting RAS signalling pathways in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Social controls on cell survival and cell death
Raff, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,604
Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,475
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Self-citation
Research works printed but not linked: 5
- Weiss, B., Bollag, G. & Shannon, K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89, 14–22 (1999). · DOI
- Singh, S. B. & Lingham, R. B. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug. Discov. Devel. 5, 225–244 (2002).
- Chen, G., Oh, S., Monia, B. P. & Stacey, D. W. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271, 28259–28265 (1996). · doi:10.1074/jbc.271.45.28259
- Reuveni, H. et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41, 10304–10314 (2002). · DOI
- Rosen, L. S. Angiogenesis inhibition in solid tumors. Cancer J. 7 (Suppl. 3), S120–S128 (2001).
Cited by
Items 101–200 of 258
Photoaffinity Labeling in Target- and Binding-Site Identification
Smith, E., & Collins, I. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.152 · Cited by 352
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
RNA polymerases I and III, growth control and cancer
White, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1551 · Cited by 333
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Tumor reversion: Correction of malignant behavior by microenvironmental cues
Kenny, P. A., & Bissell, M. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11491 · Cited by 326
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
Mechanisms of Resistance to Photodynamic Therapy
Casas, A., Di Venosa, G., Hasan, T., & Batlle, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843272 · Cited by 322
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 319
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Nissan, M. H., Pratilas, C. A., Jones, A. M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A. J., Yao, Z., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2625 · Cited by 319
Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications
Chakrabortty, S., Agrawalla, B. K., Stumper, A., Vegi, N. M., Fischer, S., Reichardt, C., Kögler, M., Dietzek, B., Feuring-Buske, M., Buske, C., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b13399 · Cited by 317
Programmable protein circuits in living cells
Gao, X. J., Chong, L. S., Kim, M. S., & Elowitz, M. B. (2018) · Science · doi:10.1126/science.aat5062 · Cited by 317
Genetics, diagnosis and management of colorectal cancer (Review)
DE ROSA, M., PACE, U., REGA, D., COSTABILE, V., DURATURO, F., IZZO, P., & DELRIO, P. (2015) · Oncology Reports · doi:10.3892/or.2015.4108 · Cited by 317
Mapping normal and cancer cell signalling networks: towards single-cell proteomics
Irish, J. M., Kotecha, N., & Nolan, G. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1804 · Cited by 316
Tumour maintenance is mediated by eNOS
Lim, K.-H., Ancrile, B. B., Kashatus, D. F., & Counter, C. M. (2008) · Nature · doi:10.1038/nature06778 · Cited by 315
Choline phospholipid metabolism: A target in cancer cells?
Ackerstaff, E., Glunde, K., & Bhujwalla, Z. M. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10659 · Cited by 315
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 311
Lim, J. K. M., Delaidelli, A., Minaker, S. W., Zhang, H.-F., Colovic, M., Yang, H., Negri, G. L., von Karstedt, S., Lockwood, W. W., Schaffer, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821323116 · Cited by 308
Elad-Sfadia, G., Haklai, R., Balan, E., & Kloog, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312697200 · Cited by 305
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Li, L., Zhao, G.-D., Shi, Z., Qi, L.-L., Zhou, L.-Y., & Fu, Z.-X. (2016) · Oncology Letters · doi:10.3892/ol.2016.5110 · Cited by 305
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
The role of oxidative stress on breast cancer development and therapy
Hecht, F., Pessoa, C. F., Gentile, L. B., Rosenthal, D., Carvalho, D. P., & Fortunato, R. S. (2016) · Tumor Biology · doi:10.1007/s13277-016-4873-9 · Cited by 303
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Inhibitor hijacking of Akt activation
Okuzumi, T., Fiedler, D., Zhang, C., Gray, D. C., Aizenstein, B., Hoffman, R., & Shokat, K. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.183 · Cited by 294
Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway
Goodwin, J. S., Drake, K. R., Rogers, C., Wright, L., Lippincott-Schwartz, J., Philips, M. R., & Kenworthy, A. K. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200502063 · Cited by 294
Shin, S., Dimitri, C. A., Yoon, S.-O., Dowdle, W., & Blenis, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.020 · Cited by 291
MEK inhibitors for the treatment of non-small cell lung cancer
Han, J., Liu, Y., Yang, S., Wu, X., Li, H., & Wang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01025-7 · Cited by 290
Rewired ERK-JNK Signaling Pathways in Melanoma
Lopez-Bergami, P., Huang, C., Goydos, J. S., Yip, D., Bar-Eli, M., Herlyn, M., Smalley, K. S. M., Mahale, A., Eroshkin, A., Aaronson, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.009 · Cited by 286
Sallmyr, A., Fan, J., & Rassool, F. V. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.036 · Cited by 285
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy
Tan, T.-T., Degenhardt, K., Nelson, D. A., Beaudoin, B., Nieves-Neira, W., Bouillet, P., Villunger, A., Adams, J. M., & White, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.008 · Cited by 284
Multiple cell death pathways as regulators of tumour initiation and progression
Jäättelä, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207513 · Cited by 283
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
Wang, H., Liu, Y., Wang, D., Xu, Y., Dong, R., Yang, Y., Lv, Q., Chen, X., & Zhang, Z. (2019) · Cells · doi:10.3390/cells8121597 · Cited by 279
Reactive oxygen species-dependent signaling regulates cancer
Weinberg, F., & Chandel, N. S. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0099-y · Cited by 275
Colorectal liver metastases: Current management and future perspectives
Martin, J., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S., Cheow, H., Duckworth, A., Heister, P., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 275
Multivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
Whiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00880.x · Cited by 273
Functional Specificity of Ras Isoforms: So Similar but So Different
Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273
Cancer genetics and drug discovery in the zebrafish
Stern, H. M., & Zon, L. I. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1126 · Cited by 272
Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development
Gustafson, A. M., Soldi, R., Anderlind, C., Scholand, M. B., Qian, J., Zhang, X., Cooper, K., Walker, D., McWilliams, A., Liu, G., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000251 · Cited by 267
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
Colorectal cancer: genetics of development and metastasis
Takayama, T., Miyanishi, K., Hayashi, T., Sato, Y., & Niitsu, Y. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1801-6 · Cited by 265
Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo
Ismail, S. A., Chen, Y.-X., Rusinova, A., Chandra, A., Bierbaum, M., Gremer, L., Triola, G., Waldmann, H., Bastiaens, P. I. H., & Wittinghofer, A. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.686 · Cited by 252
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
Platz, A., Egyhazi, S., Ringborg, U., & Hansson, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.003 · Cited by 260
Akagi, T., Sasai, K., & Hanafusa, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834876100 · Cited by 260
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
Singh, A., Sweeney, M. F., Yu, M., Burger, A., Greninger, P., Benes, C., Haber, D. A., & Settleman, J. (2012) · Cell · doi:10.1016/j.cell.2011.12.033 · Cited by 260
Li, X., Wang, J., Zhang, C., Lin, C., Zhang, J., Zhang, W., Zhang, W., Lu, Y., Zheng, L., & Li, X. (2018) · The Journal of Pathology · doi:10.1002/path.5125 · Cited by 260
YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy
Thompson, B. J. (2020) · BioEssays · doi:10.1002/bies.201900162 · Cited by 259
NMR-based functional profiling of RASopathies and oncogenic RAS mutations
Smith, M. J., Neel, B. G., & Ikura, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218173110 · Cited by 257
“RAS and its associated signaling network represent extremely attractive therapeutic targets, yet there has been minimal success at exploiting these for drug development (2, 3).”
BackgroundOsborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
The KRAS oncogene: Past, present, and future
Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.10.001 · Cited by 252
Targeting TACE-dependent EGFR ligand shedding in breast cancer
Kenny, P. A., & Bissell, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29518 · Cited by 252
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0213 · Cited by 239
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment
Dias Carvalho, P., Guimarães, C. F., Cardoso, A. P., Mendonça, S., Costa, Â. M., Oliveira, M. J., & Velho, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2084 · Cited by 202
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203
Self-citationDrugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
“FPP normally prenylates for example Ras proteins [HRAS (transforming protein p21), KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog)] through actions of farnesyl transferase (FTase) but when FTase is inhibited FPP can become a substrate for geranylgera…”
Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment
Foulds, C. E., Nelson, M. L., Blaszczak, A. G., & Graves, B. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10954-10964.2004 · Cited by 190
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183
Zona, L., Lupberger, J., Sidahmed-Adrar, N., Thumann, C., Harris, H. J., Barnes, A., Florentin, J., Tawar, R. G., Xiao, F., Turek, M., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.02.006 · Cited by 182
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
RAC1 P29S is a spontaneously activating cancer-associated GTPase
Davis, M. J., Ha, B. H., Holman, E. C., Halaban, R., Schlessinger, J., & Boggon, T. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220895110 · Cited by 180
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
Nash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172
Shi, G., DiRenzo, D., Qu, C., Barney, D., Miley, D., & Konieczny, S. F. (2013) · Oncogene · doi:10.1038/onc.2012.210 · Cited by 162
Jones, R. P., Sutton, P. A., Evans, J. P., Clifford, R., McAvoy, A., Lewis, J., Rousseau, A., Mountford, R., McWhirter, D., & Malik, H. Z. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.37 · Cited by 166
Oncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.06.002 · Cited by 169
“Both oncogenes activate mitogen-activated protein kinase (MAPK) pathways, and NRAS activates the phosphoinositide 3-kinase (PI3K) and Ral guanine nucleotide dissociation stimulator (RalGDS) pathways [25].”
BackgroundMolina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157
“In the standard model of RAS-driven tumorigenesis, oncogenic RAS protein is thought to induce the activity of a number of downstream effector enzyme families by direct interaction of GTP-bound RAS with its targets, including RAF kinases, PI3K isoforms, and guanine nucleotide exchange factors for RAL GTPases ( 4 , 34 ).”
Self-citationA hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways
Kim, D., Rath, O., Kolch, W., & Cho, K.-H. (2007) · Oncogene · doi:10.1038/sj.onc.1210230 · Cited by 166
Knight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
Wang, Y., Kim, E., Wang, X., Novitch, B. G., Yoshikawa, K., Chang, L.-S., & Zhu, Y. (2012) · Cell · doi:10.1016/j.cell.2012.06.034 · Cited by 151
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-26 · Cited by 152
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Self-citationHashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149
Konstantinidou, G., Bey, E. A., Rabellino, A., Schuster, K., Maira, M. S., Gazdar, A. F., Amici, A., Boothman, D. A., & Scaglioni, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0823 · Cited by 142
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136
RalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., & Theodorescu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1957 · Cited by 139
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Shaw, A. T., Meissner, A., Dowdle, J. A., Crowley, D., Magendantz, M., Ouyang, C., Parisi, T., Rajagopal, J., Blank, L. J., Bronson, R. T., et al. (2007) · Genes & Development · doi:10.1101/gad.1526207 · Cited by 131
Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA
Lim, K.-H., Brady, D. C., Kashatus, D. F., Ancrile, B. B., Der, C. J., Cox, A. D., & Counter, C. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00916-08 · Cited by 126
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123
Ocular Adverse Events Associated with Mek Inhibitors
Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117
Autophagic activity dictates the cellular response to oncogenic RAS
Wang, Y., Wang, X. D., Lapi, E., Sullivan, A., Jia, W., He, Y.-W., Ratnayaka, I., Zhong, S., Goldin, R. D., Goemans, C. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120193109 · Cited by 117
Shin, Y., Jeong, J. W., Wurz, R. P., Achanta, P., Arvedson, T., Bartberger, M. D., Campuzano, I. D. G., Fucini, R., Hansen, S. K., Ingersoll, J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00258 · Cited by 113
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113
Nicke, B., Bastien, J., Khanna, S. J., Warne, P. H., Cowling, V., Cook, S. J., Peters, G., Delpuech, O., Schulze, A., Berns, K., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.038 · Cited by 108
Self-citation
Metadata
- Authors
- Downward, J.
- Venue
- Nature Reviews Cancer
- Published
- 2003-01
- Volume
- 3
- Issue
- 1
- Pages
- 11-22
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2080719056
- Cited by
- 3,256
- References
- 83
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.